(Q46446514)

22 December 2017

title

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase (English)

1 reference

22 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

H Bittencourt

1

1 reference

22 December 2017

V Funke

2

1 reference

22 December 2017

L Fogliatto

3

1 reference

22 December 2017

S Magalhães

4

1 reference

22 December 2017

D Setubal

5

1 reference

22 December 2017

A Paz

6

1 reference

22 December 2017

A V Macedo

7

1 reference

22 December 2017

J Ruiz

8

1 reference

22 December 2017

A P Azambuja

9

1 reference

22 December 2017

L Silla

10

1 reference

22 December 2017

N Clementino

11

1 reference

22 December 2017

R Pasquini

12

1 reference

22 December 2017

language of work or name

English

0 references

publication date

4 August 2008

1 reference

22 December 2017

Bone Marrow Transplantation

published in

1 reference

22 December 2017

volume

42

1 reference

22 December 2017

issue

9

1 reference

22 December 2017

page(s)

597-600

1 reference

22 December 2017

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Medical management of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2008.218

1 reference

22 December 2017

1 reference

22 December 2017